Frequently Asked Questions about Alnylam Pharmaceuticals, Inc. (ALNY)

Name: Alnylam Pharmaceuticals, Inc. (ALNY) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Alnylam Pharmaceuticals, Inc. (ALNY) do?

Accepted Answer

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic ...

Question 2

Is Alnylam Pharmaceuticals, Inc. (ALNY) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of ALNY reveals an Altman Z-Score of 5.89 and a Piotroski F-Score of 6/9. These metrics, combined with its 5-year revenue trend ($3.71B most recent), help investors decide if ALNY fits their risk profile.

Question 3

What is the current P/E ratio for ALNY?

Accepted Answer

As of the latest trading session, Alnylam Pharmaceuticals, Inc. (ALNY) has a trailing P/E ratio of 135.41.

Question 4

Who is the CEO of Alnylam Pharmaceuticals, Inc.?

Accepted Answer

The current Chief Executive Officer of Alnylam Pharmaceuticals, Inc. is Yvonne L. Greenstreet.

Question 5

What was ALNY's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Alnylam Pharmaceuticals, Inc. reported annual revenues of $3.71B (2025), $2.25B (2024), $1.83B (2023), $1.04B (2022), $0.84B (2021) respectively.

Question 6

Does ALNY pay a dividend?

Accepted Answer

Alnylam Pharmaceuticals, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does ALNY have?

Accepted Answer

In its latest reporting period, Alnylam Pharmaceuticals, Inc. generated $0.47B in Free Cash Flow against a total debt load of $1.28B.

Question 8

What is the Price-to-Book (P/B) ratio of Alnylam Pharmaceuticals, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Alnylam Pharmaceuticals, Inc. (ALNY) is currently 53.83.

Question 9

What is the Price-to-Sales (P/S) ratio of ALNY?

Accepted Answer

Based on trailing twelve-month data, Alnylam Pharmaceuticals, Inc. (ALNY) trades at a Price-to-Sales (P/S) ratio of 11.47.

Question 10

What is Alnylam Pharmaceuticals, Inc.'s Return on Equity (ROE)?

Accepted Answer

Alnylam Pharmaceuticals, Inc. (ALNY) has a Return on Equity (ROE) of 90.35%, representing its profitability relative to shareholder equity.

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	3.7B	3B	501.6M	313.7M	2.39
2024-12	2.2B	1.9B	-176.9M	-278.2M	-2.18
2023-12

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	3.7B	3B	501.6M	313.7M	2.39
2024-12	2.2B	1.9B	-176.9M	-278.2M	-2.18
2023-12